NCT lookup

Inclusion Criteria:

* Adults aged ≥18 years
* Participants who have CKD stage 3-5, not on dialysis.
* POCT K+ level \>5 mmol/L to ≤5.9 mmol/L and POCT bicarbonate levels between 16-20 mmol/L inclusive prior to the first SZC dose on study Day 1
* Ability to have repeated blood draws or effective venous catheterization.
* Male and/or female. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
* Capable of giving signed informed consent

Exclusion Criteria:

* Participants with pseudohyperkalemia.
* Dialysis requirement or anticipated by the investigator to require dialysis therapy within 1 month, history of renal transplant, or life expectancy less than 3 months.
* Cardiac arrhythmias requiring immediate treatment.
* Active or suspected diabetic ketoacidosis.
* POCT bicarbonate low enough to need emergency intervention or treatment as judged by the investigator.
* Acute/chronic worsening renal function (eg, ≥30% decline in eGFR) in the 3 months before screening.
* Current acute decompensated HF, hospitalization due to decompensated HF within 4 weeks prior to screening, or myocardial infarction (MI), unstable angina, stroke or transient ischemic attack (TIA) within 12 weeks prior to screening.
* Coronary revascularization (percutaneous coronary intervention \[PCI\] or coronary artery bypass grafting \[CABG\]) or valvular repair/replacement within 12 weeks prior to screening or planned to undergo any of these operations.
* Symptomatic hypotension.
* Current exacerbation of chronic obstructive pulmonary disease (COPD)/asthma or hospitalization due to exacerbation of COPD/asthma within 4 weeks of screening.
* Severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders
* Active malignancy requiring treatment.
* History of QT prolongation associated with other medications that required discontinuation of that medication.
* Congenital long QT syndrome.
* Symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Patients with atrial fibrillation controlled by medication are permitted.
* QTcF (QT interval corrected by the Fridericia method) \>550 msec.
* Active treatment (within 7 days prior to screening) with SZC, sodium bicarbonate, sodium polystyrene sulfonate, lactulose, or patiromer

• Florence, Alabama, United States
• Chula Vista, California, United States
• Downey, California, United States
• El Centro, California, United States
• South Gate, California, United States
• Victorville, California, United States
• Aurora, Colorado, United States
• Denver, Colorado, United States
• Coral Gables, Florida, United States
• Columbus, Georgia, United States
• Hinsdale, Illinois, United States
• Kansas City, Missouri, United States
• Las Vegas, Nevada, United States
• The Bronx, New York, United States
• Asheville, North Carolina, United States
• New Bern, North Carolina, United States
• Winston-Salem, North Carolina, United States
• Providence, Rhode Island, United States
• Spartanburg, South Carolina, United States
• Chattanooga, Tennessee, United States
• Memphis, Tennessee, United States
• Dallas, Texas, United States
• Dallas, Texas, United States
• San Antonio, Texas, United States
• Shenandoah, Texas, United States
• Alexandria, Virginia, United States
• Norfolk, Virginia, United States
• Bellevue, Washington, United States
• Milwaukee, Wisconsin, United States
• San Juan, Puerto Rico